Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: DNA repair inhibitors - Ignyta/Cancer Research Technology

Next Previous
X
Search
Drug Profile

Research programme: DNA repair inhibitors - Ignyta/Cancer Research Technology

Alternative Names: RXDX-108; TEV-44229

Latest Information Update: 26 Jun 2018

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research Technology; Teva Pharmaceutical Industries
  • Developer Cancer Research Technology; Ignyta
  • Class Small molecules
  • Mechanism of Action DNA repair inhibitors; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Mar 2016 Ignyta has patents pending for RXDX 108 in USA (Ignyta 10-K, March 2016)
  • 26 Feb 2016 Discontinued - Preclinical for Cancer in United Kingdom, USA (unspecified route)
  • 17 Mar 2015 Ignyta acquires RXDX 108 and other next generation atypical protein kinase C iota inhibitors from Teva Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top